Related Experiment Video
Updated: Jul 27, 2025

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria
Bernardo Cavallazzi Sebold1,2, Junjie Li3, Guoying Ni1,3,4
1Centre for Bioinnovation, University of the Sunshine Coast, Maroochydore BC, QLD, 4558, Australia.
Abstract:
Multidrug-resistant (MDR) bacteria are considered a health threat worldwide, and this problem is set to increase over the decades. The ESKAPE, a group of six pathogens including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. is the major source of concern due to their high death incidence and nosocomial acquired infection. Host defence peptides (HDPs) are a class of ribosomally synthesised peptides that have shown promising results in combating MDR, including the ESKAPE group, in- and outside bacterial biofilms. However, their poor pharmacokinetics in physiological mediums may impede HDPs from becoming viable clinical candidates. To circumvent this problem, chemical engineering of HDPs has been seen as an emergent approach to not only improve their pharmacokinetics but also their efficacy against pathogens. In this review, we explore several chemical modifications of HDPs that have shown promising results, especially against ESKAPE pathogens, and provide an overview of the current findings with respect to each modification.
Insights
Multidrug-resistant bacteria pose a global threat. Chemical engineering of host defence peptides (HDPs) shows promise in improving their effectiveness against challenging pathogens like the ESKAPE group.
Area of Science:
- Microbiology
- Biochemistry
- Medicinal Chemistry
Background:
- Multidrug-resistant (MDR) bacteria, particularly the ESKAPE pathogens, represent a significant and growing global health concern.
- Host defence peptides (HDPs) exhibit antimicrobial activity against MDR bacteria, including within biofilms.
- The clinical application of HDPs is limited by poor pharmacokinetics in physiological environments.
Purpose of the Study:
- To review chemical modifications of HDPs aimed at enhancing their pharmacokinetic properties and antimicrobial efficacy.
- To highlight promising modifications effective against ESKAPE pathogens.
Main Methods:
- Literature review of studies involving chemically modified HDPs.
- Analysis of modifications targeting improved pharmacokinetics and antimicrobial activity.
- Focus on efficacy against Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. (ESKAPE pathogens).
Main Results:
- Various chemical modifications have successfully improved HDP pharmacokinetics.
- Modified HDPs demonstrate enhanced efficacy against ESKAPE pathogens in vitro and in vivo.
- Specific modifications offer strategies to overcome limitations of native HDPs.
Conclusions:
- Chemical engineering is a viable strategy to develop HDPs into effective clinical agents against MDR infections.
- Modified HDPs hold significant potential for combating the threat posed by ESKAPE pathogens.
- Further research into HDP modification is crucial for advancing antimicrobial therapies.
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Antibiotic Selection
Transduction
Combined Effects of Drugs: Synergism
Such synergistic combinations...

